A phase II study of brentuximab vedotin as salvage therapy for Hodgkin Lymphoma prior to autologous hematopoietic stem cell transplantation

Study Status

Open to Enrollment

Study Description

This is a clinical trial for men and women with Hodgkin Lymphoma that is no longer responding to or never responded to their first treatment.

The purpose of the study is to evaluate the safety and effectiveness of brentuximab vedotin before autologous hematopoietic stem cell transplant.

Brentuximab vedotin is a type of drug called an antibody drug conjugate (ADC). ADCs have 2 parts: a part that targets cancer cells (the antibody) and a cell killing part (the chemotherapy). Antibodies can attach to and attack specific targets on cells. The antibody part of brentuximab vedotin attaches to an important target on Hodgkin Lymphoma cells. The chemotherapy part of brentuximab vedotin kills cells to which the antibody part of the drug attaches.

Study participants will receive brentuximab vedotin via infusion once every 21 days for 4 cycles (12 weeks).

Disease Status and/or Stage

Relapsed or Refractory to One Frontline Induction Therapy


City of Hope

Key Eligibility

  • Age 18 and older
  • Hodgkin Lymphoma
  • Refractory to one frontline induction therapy or relapsed after one frontline induction therapy
  • No prior autologous or allogeneic hematopoietic stem cell transplantation
  • Detailed eligibility reviewed when you contact the study team

Principal Investigator

Peter Martin, MD


Healthy Volunteers


As a healthy volunteer in a clinical trial you may make a significant contribution to the discovery of medical knowledge and new treatments that could impact people around the world.
Click here for studies seeking healthy volunteers.

Contact Us

For general inquiries, or if you need assistance finding a study, please contact:

Robert Hagerty
Subject Recruitment Manager
Tel: (646) 962-9340
[email protected]

Top of page